Recent News

• 06.04.2025 - Jefferies Global Healthcare Conference
• 06.04.2025 - Jefferies Global Healthcare Conference
• 05.28.2025 - Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
• 05.28.2025 - Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
• 05.13.2025 - Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
• 05.13.2025 - Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
• 03.25.2025 - PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis
• 03.25.2025 - PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis
• 03.25.2025 - Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

Recent Filings

• 05.13.2025 - EX-99.1 EX-99.1
• 05.13.2025 - 8-K Current report
• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.25.2025 - ARS Annual Report to Security Holders
• 04.25.2025 - DEF 14A Other definitive proxy statements
• 04.25.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.16.2025 - 3 Initial statement of beneficial ownership of securities
• 04.16.2025 - 3 Initial statement of beneficial ownership of securities
• 04.01.2025 - 8-K Current report
• 04.01.2025 - 4 Statement of changes in beneficial ownership of securities